SCHEMBL611765

SCHEMBL611765

NC(=O)c1sc(Br)cc1NCc1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.50
ROCK2 O75116 2/20 0.50
MAP4K4 O95819 2/20 0.50
GSK3B P49841 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
MKNK2 Q9HBH9 1/20 0.50
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 2/20 0.48
EGFR P00533 1/20 0.45
MEN1 O00255 1/20 0.44
KDR P35968 5/20 0.43
FLT1 P17948 3/20 0.43
PIM1 P11309 1/20 0.43
CDK2 P24941 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611981 0.85 KDM4E (0.56) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL612035 0.84 POLB (0.49) CDC7KMT2AL3MBTL1POLBEGFR
SCHEMBL612303 0.78 MAPT (0.51) KMT2AL3MBTL1POLBEGFRKDM4E
SCHEMBL614262 0.77 CDC7 (0.65) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL613309 0.75 IKBKB (0.40) GSK3BMKNK2KMT2APOLBMEN1
SCHEMBL613467 0.74 RAB9A (0.57) KMT2AL3MBTL1POLBMEN1KDM4E
SCHEMBL614197 0.74 IKBKB (0.41) GSK3BKMT2AKDM4EALDH1A1
SCHEMBL5718472 0.74 KDM4C (0.66) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL5718299 0.74 CDC7 (0.64) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL614698 0.71 GSK3B (0.36) GSK3BMKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK CDC7 1/4885ROCK2 2920/4885MAP4K4 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.